Phase 4
Completed N=51
The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery
Post-operative Pain · Colorectal Cancer · Diverticulitis
Source: ClinicalTrials.gov NCT02052557 ↗
Enrolled (actual)
51
Serious AEs
—
Results posted
Jan 2021
Primary outcomePrimary: PCA (Patient Controlled Analgesia) Usage
◆ Published Evidence
Established
36citations · ~4 / year
Effectiveness of Liposomal Bupivacaine in Colorectal Surgery: A Pragmatic Nonsponsored Prospective Randomized Double Blinded Trial in a Community Hospital.
Summary
The purpose of the study is to evaluate the effect of Exparel on pain control and patient outcome after colon resection. The investigators will evaluate the clinical course of the patients who receive exparel as compared to the patients who do not receive exparel. Exparel is a 72 hour bupivacaine which is slowly released from lysosomes over the course of three days. A long acting local anesthetic should provide better pain control than conventional bupivacaine which has a 3.5 hour half-life.
Linked Publications
-
Effectiveness of Liposomal Bupivacaine in Colorectal Surgery: A Pragmatic Nonsponsored Prospective Randomized Double Blinded Trial in a Community Hospital.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PCA (Patient Controlled Analgesia) Usage |
— | — |
| SECONDARY Oral Pain Medications |
— | — |
| SECONDARY Total IV (Intravenous) Narcotic Used |
— | — |
| SECONDARY Total Oral Narcotic Used |
— | — |
| SECONDARY Length of Stay |
4; 6 | — |
| SECONDARY Return of Bowel Function |
— | — |
| SECONDARY Readmission |
0; 0 | — |
| SECONDARY Toradol Use |
1; 0 | — |
| SECONDARY Ofirmev |
— | — |
| SECONDARY Nausea Medication |
— | — |
| SECONDARY Foley Catheter Removal |
— | — |
| SECONDARY Postoperative Pain |
— | — |
| SECONDARY Post Operative Satisfaction |
— | — |
| SECONDARY Home Oral Narcotic Use |
2; 5 | — |
Eligibility Criteria
Inclusion Criteria
- Elective colon resection for both benign and malignant disease
- Laparoscopic, robotic and open techniques
Exclusion Criteria
- emergent colon cases
- cases preformed by surgeons other than Dr. Raman or Dr. Kraemer
- pregnant patients
- patients currently breast feeding
- patients under the age of 18
- other patients unable to give informed consent
- bupivacaine use within 96 hours
- allergy to amide anesthetics
- prisoners
- caution will be used in patients with renal or hepatic failure.
Data sourced from ClinicalTrials.gov (NCT02052557) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.